IP Library Granted Patent US 9,421,238
Granted Patent B2
US 9,421,238 · App. 14/767,985 · Granted Aug 23, 2016

Treatment of klebsiella pneumoniae with liposomally formulated glutathione

Inventors: Lou Ann Brown (Atlanta, GA); Frederick Timothy Guilford (Palo Alto, CA)
Assignees: YOUR ENERGY SYSTEMS, LLC; EMORY UNIVERSITY; CHILDREN'S HALTHCARE OF ATLANTA, INC.
A61K38/063A61K9/127A61K9/006A61K9/0014A61K9/0019A61K9/0095A61K9/4858
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,421,238
App. No.
14/767,985
Granted
Aug 23, 2016
Kind
B2
Abstract

The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.

Claims (8)

1. A method of treating a Klebsiella pneumoniae infection in a mammalian patient comprising:

orally administering liposomally formulated reduced glutathione, said liposomally formulated reduced glutathione being formulated from at least one phospholipid selected from the group of phosphatidylethanolamine or phosphatidylserine, wherein the reduced glutathione included inside the liposome is in an amount of at least 3.3% w/w.

2. A method of treating a Klebsiella pneumoniae infection in a mammalian patient comprising:

orally administering liposomally formulated reduced glutathione, said liposomally formulated reduced glutathione being formulated from lecithin, wherein the reduced glutathione included inside the liposome is in an amount of at least 3.3% w/w.

3. A method of treating a Klebsiella pneumoniae infection in a mammalian patient comprising:

orally administering liposomally formulated reduced glutathione, said liposomally formulated reduced glutathione being formulated from at least one ceramide, wherein the reduced glutathione included inside the liposome is in an amount of at least 3.3% w/w.

4. A method of treating a Klebsiella pneumoniae infection in a mammalian patient comprising:

orally administering liposomally formulated reduced glutathione, said liposomally formulated reduced glutathione being formulated from at least one cardiolipin, wherein the reduced glutathione included inside the liposome is in an amount of at least 3.3% w/w.

Continuity (2)
Provisional Application 61765379 · Feb 15, 2013
Related Publication 20150366933A1 · Dec 24, 2015